RECODE: Design and baseline results of a cluster randomized trial on cost-effectiveness of integrated COPD management in primary care

BMC Pulmonary Medicine

Niels H Chavannes²  Apostolos Tsiachristas¹  Jacobijn Gussekloo²  Maureen PMH Rutten-van Mölken¹  Willem JJ Assendelft³  Catharina H Schoonvelde²  Melinde RS Boland¹  Annemarije L Kruis² 

[1] Institute for Medical Technology Assessment, Erasmus University, PO Box 1738, Rotterdam, DR, 3000, the Netherlands;Dept of Public Health and Primary Care, Leiden University Medical Centre, P.O. Box 9600, Leiden, RC, 2300, The Netherlands;Dept of Primary and Community Care, Radboud University Nijmegen Medical Center, PO Box 9101, Nijmegen, HB, 6500, the Netherlands

关键词: Integrated care;    Cost-effectiveness;    Primary care;    Disease management;    COPD;   

Others  :  1122384
DOI  :  10.1186/1471-2466-13-17

 received in 2013-03-15, accepted in 2013-03-18,  发布年份 2013

【 摘 要 】

Background

Favorable effects of formal pulmonary rehabilitation in selected moderate to severe COPD patients are well established. Few data are available on the effects and costs of integrated disease management (IDM) programs on quality of care and health status of COPD patients in primary care, representing a much larger group of COPD patients. Therefore, the RECODE trial assesses the long-term clinical and cost-effectiveness of IDM in primary care.

Methods/design

RECODE is a cluster randomized trial with two years of follow-up, during which 40 clusters of primary care teams (including 1086 COPD patients) are randomized to IDM or usual care. The intervention started with a 2-day multidisciplinary course in which healthcare providers are trained as a team in essential components of effective COPD IDM in primary care. During the course, the team redesigns the care process and defines responsibilities of different caregivers. They are trained in how to use feedback on process and outcome data to guide implement guideline-driven integrated healthcare. Practice-tailored feedback reports are provided at baseline, and at 6 and 12 months. The team learns the details of an ICT program that supports recording of process and outcome measures. Afterwards, the team designs a time-contingent individual practice plan, agreeing on steps to be taken in order to integrate a COPD IDM program into daily practice. After 6 and 12 months, there is a refresher course for all teams simultaneously to enable them to learn from each other’s experience. Health status of patients at 12 months is the primary outcome, measured by the Clinical COPD Questionnaire (CCQ). Secondary outcomes include effects on quality of care, disease-specific and generic health-related quality of life, COPD exacerbations, dyspnea, costs of healthcare utilization, and productivity loss.

Discussion

This article presents the protocol and baseline results of the RECODE trial. This study will allow to evaluate whether IDM implemented in primary care can positively influence quality of life and quality of care in mild to moderate COPD patients, thereby making the benefits of multidisciplinary rehabilitation applicable to a substantial part of the COPD population.

Trial registration

Netherlands Trial Register (NTR): NTR2268

【 授权许可】

   
2013 Kruis et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]GOLD: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2013.
• [2]Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW: Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008, 178:332-338.
• [3]Agusti A, Calverley PM, Celli B, Coxson HO, Edwards LD, Lomas DA: Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010, 11:122.
• [4]Rabe KF, Wedzicha JA: Controversies in treatment of chronic obstructive pulmonary disease. Lancet 2011, 378:1038-1047.
• [5]Nici L, Zuwallack R: An official American Thoracic Society workshop report: the Integrated Care of The COPD Patient. Proc Am Thorac Soc 2012, 9:9-18.
• [6]Weingarten SR, Henning JM, Badamgarav E, Knight K, Hasselblad V, Gano A Jr: Interventions used in disease management programmes for patients with chronic illness-which ones work? Meta-analysis of published reports. BMJ 2002, 325:925.
• [7]Lacasse Y, Goldstein R, Lasserson TJ, Martin S: Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009., CD003793
• [8]Berry MJ, Rejeski WJ, Adair NE, Zaccaro D: Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med 1999, 160:1248-1253.
• [9]Nici L, Donner C, Wouters E, Zuwallack R, Ambrosino N, Bourbeau J: American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006, 173:1390-1413.
• [10]Landry MD, Hamdan E, Al MS, Brooks D: The precarious balance between 'supply' and 'demand' for health care: the increasing global demand for rehabilitation service for individuals living with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2008, 3:393-396.
• [11]Yohannes AM, Connolly MJ: Pulmonary rehabilitation programmes in the UK: a national representative survey. Clin Rehabil 2004, 18:444-449.
• [12]Brooks D, Sottana R, Bell B, Hanna M, Laframboise L, Selvanayagarajah S: Characterization of pulmonary rehabilitation programs in Canada in 2005. Can Respir J 2007, 14:87-92.
• [13]Tiep BL: Disease management of COPD with pulmonary rehabilitation. Chest 1997, 112:1630-1656.
• [14]Ries AL, Kaplan RM, Limberg TM, Prewitt LM: Effects of pulmonary rehabilitation on physiologic and psychosocial outcomes in patients with chronic obstructive pulmonary disease. Ann Intern Med 1995, 122:823-832.
• [15]Griffiths TL, Burr ML, Campbell IA, Lewis-Jenkins V, Mullins J, Shiels K: Results at 1 year of outpatient multidisciplinary pulmonary rehabilitation: a randomised controlled trial. Lancet 2000, 355:362-368.
• [16]Vale F, Reardon JZ, ZuWallack RL: The long-term benefits of outpatient pulmonary rehabilitation on exercise endurance and quality of life. Chest 1993, 103:42-45.
• [17]Guyatt GH, Berman LB, Townsend M: Long-term outcome after respiratory rehabilitation. CMAJ 1987, 137:1089-1095.
• [18]Strijbos JH, Postma DS, van Altena R, Gimeno F, Koeter GH: A comparison between an outpatient hospital-based pulmonary rehabilitation program and a home-care pulmonary rehabilitation program in patients with COPD. A follow-up of 18 months. Chest 1996, 109:366-372.
• [19]Kruis AL, Chavannes NH: Potential benefits of integrated COPD management in primary care. Monaldi Arch Chest Dis 2010, 73:130-134.
• [20]Chavannes NH, Grijsen M, van den Akker M, Schepers H, Nijdam M, Tiep B: Integrated disease management improves one-year quality of life in primary care COPD patients: a controlled clinical trial. Prim Care Respir J 2009, 18:171-176.
• [21]Chavannes N: Integrated Chronic Obstructive Pulmonary Disease Management in Primary Care. Dis Manage Health Outcomes 2008, 16:315-318.
• [22]Adams R, Chavannes N, Jones K, Ostergaard MS, Price D: Exacerbations of chronic obstructive pulmonary disease–a patients' perspective. Prim Care Respir J 2006, 15:102-109.
• [23]Lemmens KM, Nieboer AP, Huijsman R: A systematic review of integrated use of disease-management interventions in asthma and COPD. Respir Med 2009, 103:670-691.
• [24]Steuten LM, Lemmens KM, Nieboer AP, Vrijhoef HJ: Identifying potentially cost effective chronic care programs for people with COPD. Int J Chron Obstruct Pulmon Dis 2009, 4:87-100.
• [25]Kruis AL, Van AJ, Erkelens MR, Scheepers H, In V, Muris JW: Sustained effects of integrated COPD management on health status and exercise capacity in primary care patients. Int J Copd 2010, 5:407-413.
• [26]Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A: Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
• [27]Smeele IJM, van Weel C, van Schayck CP, van der Molen T, Thoonen B, Schermer T: Dutch College of General Practitioners Guideline for COPD Diagnosis. Huisarts Wet 2007, 50:362-379.
• [28]Smelt AF, van der Weele GM, Blom JW, Gussekloo J, Assendelft WJ: How usual is usual care in pragmatic intervention studies in primary care? An overview of recent trials. Br J Gen Pract 2010, 60:e305-e318.
• [29]Kocks JW, Tuinenga MG, Uil SM, van den Berg JW, Stahl E, van der Molen T: Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire. Respir Res 2006, 7:62. BioMed Central Full Text
• [30]van der Molen T, Willemse BW, Schokker S, ten Hacken NH, Postma DS, Juniper EF: Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes 2003, 1:13. BioMed Central Full Text
• [31]Jones PW: St. George's Respiratory Questionnaire: MCID. COPD 2005, 2:75-79.
• [32]Lamers LM, McDonnell J, Stalmeier PF, Krabbe PF, Busschbach JJ: The Dutch tariff: results and arguments for an effective design for national EQ-5D valuation studies. Health Econ 2006, 15:1121-1132.
• [33]The Euro Qol Group: Euro Qol-a new facility for the measurement of health-related quality of life. 199–208. Amsterdam, the Netherlands: Health Policy; 1990.
• [34]Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R: Translation, validation, and norming of the Dutch language version of the SF-36 Health Survey in community and chronic disease populations. J Clin Epidemiol 1998, 51:1055-1068.
• [35]Schuurmans H, Steverink N, Frieswijk N, Buunk BP, Slaets JP, Lindenberg S: How to measure self-management abilities in older people by self-report. The development of the SMAS-30. Qual Life Res 2005, 14:2215-2228.
• [36]Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA: Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999, 54:581-586.
• [37]Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM: Development and validation of the Patient Assessment of Chronic Illness Care (PACIC). Med Care 2005, 43:436-444.
• [38]Bonomi AE, Wagner EH, Glasgow RE, VonKorff M: Assessment of chronic illness care (ACIC): a practical tool to measure quality improvement. Health Serv Res 2002, 37:791-820.
• [39]Devane D, Begley CM, Clarke M: How many do I need? Basic principles of sample size estimation. J Adv Nurs 2004, 47:297-302.
• [40]Donner A, Birkett N, Buck C: Randomization by cluster. Sample size requirements and analysis. Am J Epidemiol 1981, 114:906-914.
• [41]Smeeth L, Ng ES: Intraclass correlation coefficients for cluster randomized trials in primary care: data from the MRC Trial of the Assessment and Management of Older People in the Community. Contr Clin Trials 2002, 23:409-421.
• [42]Snijders TAB, Bosker RJ: Multilevel Analysis: An Introduction to Basic and Advanced Multilevel Modeling. London: Sage Publishers; 2011.
• [43]Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A: Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report. Value Health 2005, 8:521-533.
• [44]College voor Zorgverzekeringen: Dutch guidelines for pharmacoeconomic research, evaluation and update. Diemen: Dutch Health Insurance Council; 2006.
• [45]Koopmanschap MA, Rutten FF, Van Ineveld BM, Van RL: The friction cost method for measuring indirect costs of disease. J Health Econ 1995, 14:171-189.
• [46]Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ: Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469.
• [47]Al MJ: Cost-effectiveness acceptability curves revisited. Pharmacoeconomics 2013, 31:93-100.
• [48]Fenwick E, O'Brien BJ, Briggs A: Cost-effectiveness acceptability curves-facts, fallacies and frequently asked questions. Health Econ 2004, 13:405-415.
• [49]Fenwick E, Claxton K, Sculpher M: Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001, 10:779-787.
• [50]Stinnett AA, Mullahy J: Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Med Decis Making 1998, 18:S68-S80.
• [51]Boxall AM, Barclay L, Sayers A, Caplan GA: Managing chronic obstructive pulmonary disease in the community, A randomized controlled trial of home-based pulmonary rehabilitation for elderly housebound patients. J Cardiopulm Rehabil 2005, 25:378-385.
• [52]Fernandez AM, Pascual J, Ferrando C, Arnal A, Vergara I, Sevila V: Home-based pulmonary rehabilitation in very severe COPD: is it safe and useful? J Cardiopulm Rehabil Prev 2009, 29:325-331.
• [53]Gottlieb V, Lyngso AM, Nybo B, Frolich A, Backer V: Pulmonary rehabilitation for moderate COPD (GOLD 2)–does it have an effect? COPD 2011, 8:380-386.
• [54]Rea H, McAuley S, Stewart A, Lamont C, Roseman P, Didsbury P: A chronic disease management programme can reduce days in hospital for patients with chronic obstructive pulmonary disease. Intern Med J 2004, 34:608-614.
• [55]van Wetering CR, Hoogendoorn M, Mol SJ, Rutten-van Molken MP, Schols AM: Short- and long-term efficacy of a community-based COPD management programme in less advanced COPD: a randomised controlled trial. Thorax 2010, 65:7-13.
• [56]Trappenburg JC, Koevoets L, de Weert-van Oene GH, Monninkhof EM, Bourbeau J, Troosters T: Action Plan to enhance self-management and early detection of exacerbations in COPD patients; a multicenter RCT. BMC Pulm Med 2009, 9:52. BioMed Central Full Text
• [57]Herland K, Akselsen JP, Skjonsberg OH, Bjermer L: How representative are clinical study patients with asthma or COPD for a larger "real life" population of patients with obstructive lung disease? Respir Med 2005, 99:11-19.